Article Type
Article
Changed
Fri, 03/22/2024 - 10:44
Display Headline
Cancer Data Trends 2024: Multiple Myeloma

Click here to view more from Cancer Data Trends 2024.

References

1. Mahmood S, Gupta P, Ma H. Impact of time period of diagnosis, race, and military exposures on the survival of US military veterans with multiple myeloma and/or plasmacytoma. J Clin Oncol. 2023;41(16 suppl). Abstract e20061. https://doi.org/10.1200/jco.2023.41.16_suppl.e20061  

2. National Cancer Institute. Cancer stat facts: myeloma. Accessed January 2, 2024. https://seer.cancer.gov/statfacts/html/mulmy.html 

3. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2022;33(1):117]. Ann Oncol. 2021;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014 

4. Su CT, Chen JC, Sussman JB. Virtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of Veterans Health Administration data. Leuk Lymphoma. 2023;64(5):1035-1039. doi: 10.1080/10428194.2023.2189989 

5. O’Donnell EK, Shapiro YN, Yee AJ, et al. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer. 2022;128(10):1996-2004. doi: 10.1002/cncr.34134 

6. O’Donnell EK, Shapiro YN, Yee AJ, et al. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv. 2022;6(17):4967-4974. doi: 10.1182/bloodadvances.2022007127 

7. Ahmed N, Shahzad M, Shippey E, et al. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplant Cell Ther. 2022;28(7):358-364. doi: 10.1016/j.jtct.2022.04.008 

 

Author and Disclosure Information

Reviewed by Christopher Su, MD, MPH
Assistant Professor, Division of Hematology and Oncology
University of Washington
Fred Hutchinson Cancer Center
Seattle, WA

Dr. Su has no relevant financial relationships to disclose.

Publications
Federal Practitioner
Topics
Multiple Myeloma
Cancer
Author and Disclosure Information

Reviewed by Christopher Su, MD, MPH
Assistant Professor, Division of Hematology and Oncology
University of Washington
Fred Hutchinson Cancer Center
Seattle, WA

Dr. Su has no relevant financial relationships to disclose.

Author and Disclosure Information

Reviewed by Christopher Su, MD, MPH
Assistant Professor, Division of Hematology and Oncology
University of Washington
Fred Hutchinson Cancer Center
Seattle, WA

Dr. Su has no relevant financial relationships to disclose.

Click here to view more from Cancer Data Trends 2024.

Click here to view more from Cancer Data Trends 2024.

References

1. Mahmood S, Gupta P, Ma H. Impact of time period of diagnosis, race, and military exposures on the survival of US military veterans with multiple myeloma and/or plasmacytoma. J Clin Oncol. 2023;41(16 suppl). Abstract e20061. https://doi.org/10.1200/jco.2023.41.16_suppl.e20061  

2. National Cancer Institute. Cancer stat facts: myeloma. Accessed January 2, 2024. https://seer.cancer.gov/statfacts/html/mulmy.html 

3. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2022;33(1):117]. Ann Oncol. 2021;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014 

4. Su CT, Chen JC, Sussman JB. Virtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of Veterans Health Administration data. Leuk Lymphoma. 2023;64(5):1035-1039. doi: 10.1080/10428194.2023.2189989 

5. O’Donnell EK, Shapiro YN, Yee AJ, et al. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer. 2022;128(10):1996-2004. doi: 10.1002/cncr.34134 

6. O’Donnell EK, Shapiro YN, Yee AJ, et al. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv. 2022;6(17):4967-4974. doi: 10.1182/bloodadvances.2022007127 

7. Ahmed N, Shahzad M, Shippey E, et al. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplant Cell Ther. 2022;28(7):358-364. doi: 10.1016/j.jtct.2022.04.008 

 

References

1. Mahmood S, Gupta P, Ma H. Impact of time period of diagnosis, race, and military exposures on the survival of US military veterans with multiple myeloma and/or plasmacytoma. J Clin Oncol. 2023;41(16 suppl). Abstract e20061. https://doi.org/10.1200/jco.2023.41.16_suppl.e20061  

2. National Cancer Institute. Cancer stat facts: myeloma. Accessed January 2, 2024. https://seer.cancer.gov/statfacts/html/mulmy.html 

3. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2022;33(1):117]. Ann Oncol. 2021;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014 

4. Su CT, Chen JC, Sussman JB. Virtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of Veterans Health Administration data. Leuk Lymphoma. 2023;64(5):1035-1039. doi: 10.1080/10428194.2023.2189989 

5. O’Donnell EK, Shapiro YN, Yee AJ, et al. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer. 2022;128(10):1996-2004. doi: 10.1002/cncr.34134 

6. O’Donnell EK, Shapiro YN, Yee AJ, et al. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv. 2022;6(17):4967-4974. doi: 10.1182/bloodadvances.2022007127 

7. Ahmed N, Shahzad M, Shippey E, et al. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplant Cell Ther. 2022;28(7):358-364. doi: 10.1016/j.jtct.2022.04.008 

 

Publications
Federal Practitioner
Publications
Federal Practitioner
Topics
Multiple Myeloma
Cancer
Article Type
Article
Display Headline
Cancer Data Trends 2024: Multiple Myeloma
Display Headline
Cancer Data Trends 2024: Multiple Myeloma
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
SLIDESHOW
Use ProPublica
CFC Schedule Remove Status
Mon, 03/11/2024 - 17:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Slide
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media
Caption
<p>Multiple myeloma has been associated with improved overall survival at the VA since 2000.<sup>1</sup> Advances in diagnostics, response assessment (eg, minimal residual disease detection), and novel therapies (eg, autologous stem cell transplant and cellular immunotherapy) have likely contributed to this increase.<sup>1-3</sup>&nbsp;However, tobacco use, military exposures, and older age at diagnosis still correlate with negative outcomes.<sup>1</sup></p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p><sup>SEER, Surveillance, Epidemiology, and End Results Program.</sup></p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p>Despite a large shift from in-person to virtual care at the start of the pandemic, the nonsignificant trends in inpatient admissions and numbers of oral prescriptions for multiple myeloma suggest that there were no drastic changes in quality of care—although longer-term impacts on survival and quality-of-life measures have yet to be observed.</p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p>Multiple myeloma treatment takes a toll on patients and caregivers. Recent surveys have found that both groups have significant rates of anxiety and depression, as well as misconceptions about disease prognosis that may cause further distress as treatment progresses. This highlights the importance of ongoing open dialogue and detailed discussions among physicians, patients, and caregivers.&nbsp;</p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p>Although CAR T-cell therapy has been a revolutionary breakthrough in the treatment of relapsed/refractory hematologic malignancies, significant barriers to equitable care remain. Among these include&nbsp;racial underrepresentation in clinical trials, affordability, and long distances to facilities offering CAR T-cell therapy.&nbsp;</p>
Disable zoom
Off
Media Folder
Media Root